As discussed earlier, the upregulation of UCP-2 and UCP-3 was found to contribute to skeletal muscle loss during cancer cachexia, although some studies indicated that the upregulation of UCPs does not have any direct effect on skeletal muscle loss. The gene discussed is UCP2; the disease is cancer.